The North America Idiopathic Pulmonary Fibrosis Market would witness market growth of 5.6% CAGR during the forecast period (2021-2027).
Idiopathic pulmonary fibrosis is a sort of chronic scarring lung disease that causes a steady reduction in lung function that's irreversible. In addition, shortness of breath and a persistent dry, hacking cough are the most prevalent indications and symptoms of idiopathic pulmonary fibrosis. Moreover, many people who are impacted also observe a decrease in appetite and weight loss over time. Due to a lack of oxygen, some persons with idiopathic pulmonary fibrosis acquire enlarged and rounded tips of the fingers and toes (clubbing).
While it's difficult to define who develops IPF, some studies showcase that more male women are diagnosed with the disease than females. Age is also a determining factor in IPF. In a vast number of researches, older age has been identified as a prevalent diagnostic factor for IPF.
According to the Centers for Disease Control and Prevention, more than 14% (34.1 million) of adults in the United States smoked tobacco in 2019. As per the American IPF Foundation, the incidence of idiopathic pulmonary fibrosis (IPF) has doubled in the last ten years. In the United States, an estimated 50,000 people die from IPF each year, which is higher than breast cancer.
Moreover, the Centers for Disease Control and Prevention recently discovered a statistically significant cluster of IPF patients diagnosed at a Virginia medical centre. Because of the increased frequency of the condition, as well as the rising geriatric population and smoking habits, the United States is a prominent country of the regional market. In the United States, idiopathic pulmonary fibrosis treatment costs $100,000 per year, according to data published in the American Journal of Managed Care (AJMC) in 2014.
The US market dominated the North America Idiopathic Pulmonary Fibrosis Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $1,269.5 million by 2027. The Canada market is poised to grow at a CAGR of 8% during (2021 - 2027). Additionally, The Mexico market would display a CAGR of 7% during (2021 - 2027).
Based on Drug Type, the market is segmented into Pirfenidone and Nintedanib. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Idiopathic Pulmonary Fibrosis Market is Estimated to reach $4.7 Billion by 2027, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- GNI Group Ltd.
- Shionogi & Co., Ltd.
- Mission Therapeutics Ltd.
- Galapagos NV
- FibroGen, Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Biogen, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Idiopathic Pulmonary Fibrosis Market, by Drug Type
1.4.2 North America Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
1.4.3 North America Idiopathic Pulmonary Fibrosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
Chapter 4. North America Idiopathic Pulmonary Fibrosis Market by Drug Type
4.1 North America Pirfenidone Market by Country
4.2 North America Nintedanib Market by Country
Chapter 5. North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel
5.1 North America Retail Pharmacies Market by Country
5.2 North America Hospital Pharmacies Market by Country
5.3 North America Online Providers Market by Country
Chapter 6. North America Idiopathic Pulmonary Fibrosis Market by Country
6.1 US Idiopathic Pulmonary Fibrosis Market
6.1.1 US Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.2 US Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2 Canada Idiopathic Pulmonary Fibrosis Market
6.2.1 Canada Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.2 Canada Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3 Mexico Idiopathic Pulmonary Fibrosis Market
6.3.1 Mexico Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.2 Mexico Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4 Rest of North America Idiopathic Pulmonary Fibrosis Market
6.4.1 Rest of North America Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.2 Rest of North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 GNI Group Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Shionogi & Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Mission Therapeutics Ltd.
7.3.1 Company Overview
7.4 Galapagos NV
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 FibroGen, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals and Trials:
7.7.5.2 Acquisitions and Mergers:
7.8 Bristol Myers Squibb Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. Biogen, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
TABLE 1 North America Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 2 North America Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements – Idiopathic Pulmonary Fibrosis Market
TABLE 4 Approvals and Trials – Idiopathic Pulmonary Fibrosis Market
TABLE 5 Acquisition and Mergers – Idiopathic Pulmonary Fibrosis Market
TABLE 6 North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 7 North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 8 North America Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 9 North America Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 10 North America Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 11 North America Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 12 North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 13 North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 14 North America Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 15 North America Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 16 North America Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 17 North America Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 18 North America Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 19 North America Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 20 North America Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 21 North America Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 22 US Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 23 US Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 24 US Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 25 US Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 26 US Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 27 US Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 28 Canada Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 29 Canada Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 30 Canada Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 31 Canada Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 32 Canada Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 33 Canada Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 34 Mexico Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 35 Mexico Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 36 Mexico Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 37 Mexico Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 38 Mexico Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 39 Mexico Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 40 Rest of North America Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 41 Rest of North America Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 42 Rest of North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 43 Rest of North America Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 44 Rest of North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 45 Rest of North America Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 46 Key Information – GNI Group Ltd.
TABLE 47 Key Information – Shionogi & Co., Ltd.
TABLE 48 Key Information – Mission Therapeutics Ltd.
TABLE 49 Key Information – Galapagos NV
TABLE 50 Key Information – FibroGen, Inc.
TABLE 51 Key Information – AstraZeneca PLC
TABLE 52 key information – F. Hoffmann-La Roche Ltd.
TABLE 53 Key Information – Bristol Myers Squibb Company
TABLE 54 Key Information – Boehringer Ingelheim International GmbH
TABLE 55 Key Information – Biogen, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.